The Globe and Mail reports in its Wednesday, Nov. 15, edition that Stifel analyst Justin Keywood has reaffirmed his "buy" recommendation for Hamilton Thorne. The Globe's David Leeder writes that Mr. Keywood snipped his share target back by 25 cents to $2.75. Analysts on average target the shares at $2.32. Mr. Keywood says in a note: "Hamilton Thorne, a leading supplier into the fertility industry, reported Q3 results that were somewhat of a rare miss on estimates but with still 5-per-cent organic growth. The quarter was impacted by unexpected headwinds with equipment sales in China, along with a recall by a contract manufacturer on two product lines. Looking forward, management has guided for a strong Q4 with 9- to 10-per-cent organic growth, 15-per-cent overall growth and 19-per-cent adjusted EBITDA margin. The product recall appears to be temporary, and we anticipate 20-per-cent growth in F2024 with improving margins on the back of price increases and completed investments in manufacturing capacity. The recent Gynetics acquisition will also bolster growth." The Globe reported on April 10 that iA Capital Markets analyst Chelsea Stellick was keen on Hamilton Thorne. The shares could then be had for $1.76.